21 results
8-K
EX-10.1
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration
8-K
EX-10.1
AXLA
Axcella Health Inc.
23 Sep 22
Entry into a Material Definitive Agreement
4:01pm
. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory
8-K
EX-10.1
AXLA
Axcella Health Inc.
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint
8-K
EX-10.1
AXLA
Axcella Health Inc.
3 Mar 21
Axcella Announces Alison D. Schecter, M.D., as President of R&D
5:26pm
of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
25. Successor
8-K
EX-10.1
rafrhm yq
25 Nov 19
Axcella Strengthens Executive Team with Key Addition and Promotion
8:11am
424B4
e1a6sop h14
9 May 19
Prospectus supplement with pricing info
4:29pm
S-1/A
xqkxwk3m u40e6vre
30 Apr 19
IPO registration (amended)
6:06am
S-1/A
EX-10.16
f975cefnms447
30 Apr 19
IPO registration (amended)
6:06am
S-1/A
EX-10.3
pwrdm0d gmhfj
30 Apr 19
IPO registration (amended)
6:06am
S-1
n3c 6q8c7x
12 Apr 19
IPO registration
7:02am
DRS/A
qpoh3o4ighgckc0
15 Mar 19
Draft registration statement (amended)
12:00am